Bioventus (NASDAQ:BVS) Sees Large Volume Increase – Here’s Why
by Tristan Rich · The Markets DailyShares of Bioventus Inc. (NASDAQ:BVS – Get Free Report) saw unusually-strong trading volume on Wednesday . 489,148 shares changed hands during trading, a decline of 4% from the previous session’s volume of 506,912 shares.The stock last traded at $14.51 and had previously closed at $13.42.
Analyst Ratings Changes
BVS has been the topic of several research reports. Barrington Research set a $18.00 price target on shares of Bioventus in a research note on Thursday. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research report on Tuesday, June 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Finally, Craig Hallum reaffirmed a “buy” rating and set a $18.00 price objective on shares of Bioventus in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $16.25.
View Our Latest Analysis on Bioventus
Bioventus Stock Performance
The business’s fifty day simple moving average is $10.70 and its 200-day simple moving average is $9.66. The firm has a market cap of $1.16 billion, a P/E ratio of 18.09, a price-to-earnings-growth ratio of 1.94 and a beta of 0.63. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08.
Bioventus (NASDAQ:BVS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. The firm had revenue of $153.21 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 29.77%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, sell-side analysts expect that Bioventus Inc. will post 0.79 earnings per share for the current year.
Institutional Investors Weigh In On Bioventus
Institutional investors and hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC raised its holdings in shares of Bioventus by 4.1% during the fourth quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock valued at $44,993,000 after acquiring an additional 236,741 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Bioventus by 4.4% in the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock valued at $19,567,000 after acquiring an additional 122,749 shares in the last quarter. Geode Capital Management LLC increased its position in Bioventus by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock valued at $8,337,000 after purchasing an additional 19,388 shares during the period. State Street Corp increased its position in Bioventus by 1.7% during the 4th quarter. State Street Corp now owns 891,024 shares of the company’s stock valued at $6,629,000 after purchasing an additional 14,590 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Bioventus by 14.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock worth $7,971,000 after purchasing an additional 107,930 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.
About Bioventus
Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.